Nanocarriers-based therapeutic strategy for drug-resistant epilepsy: a systematic review
Background - Nanocarriers have been proposed as a solution for drug-resistant epilepsy. - Methods - A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus fro...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
5 January 2025
|
| In: |
International journal of pharmaceutics
Year: 2025, Volume: 668, Pages: 1-12 |
| ISSN: | 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2024.124986 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ijpharm.2024.124986 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0378517324012201 |
| Author Notes: | Roberto Diaz-Peregrino, Daniel San-Juan, Carlos Patiño-Ramirez, Lenin V. Sandoval-Luna, Aleida Arritola-Uriarte |
| Summary: | Background - Nanocarriers have been proposed as a solution for drug-resistant epilepsy. - Methods - A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus from March 2023 to March 2024. - Results - Eighteen studies were identified: 2 in vitro, 9 in vivo, and 7 combined. While epilepsy models and seizure control assessments were consistent, there was variability in evaluating the potential toxicity of nanocarriers. Only one study did not show a reduction in brain inflammation, seizures, and cell loss. Nanocarrier toxicity was evaluated just in six studies, all of which indicated low toxicity both in vitro and in vivo. - Conclusions - Nanocarriers with antiseizure drugs manage seizures, inflammation, oxidative stress, and behavior impairment in drug-resistant epilepsy. Furthermore, nanocarriers are a safe option for delivering antiseizure drugs, though more research is needed to confirm these findings. |
|---|---|
| Item Description: | Online veröffentlicht: 22. November 2024, Artikelversion: 25. November 2024 Gesehen am 17.09.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1873-3476 |
| DOI: | 10.1016/j.ijpharm.2024.124986 |